Table 12 Proportion of Subjects with Central Serum Potassium <5.5 mEq/L Over Time (ITT Population)

	Spironolactone + Placebo (N=148)						Spironolactone + Patiromer (N=147)					
	Baseline Central Serum Potassium 4.3-<4.7 mEq/L		Baseline Central Serum Potassium 4.7-<5.1 mEq/L		Overall		Baseline Central Serum Potassium 4.3-<4.7 mEq/L		Baseline Central Serum Potassium 4.7-<5.1 mEq/L		Overall	
	N	n (%)	N	n (%)	N	n (%)	N	n (%)	N	n (%)	N	n (%)
≤Week 1	66	62 (93.9%)	80	66 (82.5%)	146	128 (87.7%)	63	60 (95.2%)	83	75 (90.4%)	146	135 (92.5%)
>Week 1 and ≤Week 2	66	57 (86.4%)	81	65 (80.2%)	147	122 (83.0%)	63	57 (90.5%)	84	74 (88.1%)	147	131 (89.1%)
>Week 2 and ≤Week 3	65	63 (96.9%)	80	65 (81.3%)	145	128 (88.3%)	63	59 (93.7%)	83	74 (89.2%)	146	133 (91.1%)
>Week 3 and ≤Week 4	66	60 (90.9%)	79	61 (77.2%)	145	121 (83.4%)	63	61 (96.8%)	82	74 (90.2%)	145	135 (93.1%)
>Week 4 and ≤Week 6	66	61 (92.4%)	79	64 (81.0%)	145	125 (86.2%)	62	61 (98.4%)	82	79 (96.3%)	144	140 (97.2%)
>Week 6 and ≤Week 8	65	58 (89.2%)	77	66 (85.7%)	142	124 (87.3%)	62	61 (98.4%)	82	74 (90.2%)	144	135 (93.8%)
>Week 8 and ≤Week 10	63	58 (92.1%)	75	66 (88.0%)	138	124 (89.9%)	61	58 (95.1%)	81	72 (88.9%)	142	130 (91.5%)
>Week 10 and ≤Week 12	64	61 (95.3%)	76	65 (85.5%)	140	126 (90.0%)	62	61 (98.4%)	82	80 (97.6%)	144	141 (97.9%)

Notes: Two baseline potassium subgroups, 4.3-<4.7 mEq/L versus 4.7-5.1 mEq/L, are based on central laboratory data. If a subject's serum potassium result is not in one of these two subgroups, the subject's potassium stratum at randomization was used.
Denominators at a time interval are the number of subjects with serum potassium data. During a time interval, a subject's serum potassium may be <5.5 mEq/L more than once due to unscheduled visits. In this case, the subject was counted once in that time interval.
ITT=Intent-to-treat.